ICIQ Urinary Incontinence Short Form (ICIQ-SF)
Also known as: ICIQ-SF, ICIQ
The ICIQ-SF is a brief, four-item self-report measure designed to assess the frequency, severity, and impact of urinary incontinence symptoms in both men and women. Developed by Avery and colleagues in 2004, it combines high psychometric utility with practical brevity, making it ideal for routine clinical screening and outcome measurement in primary care, urology, and gynecology settings.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The ICIQ-SF is appropriate for adults (≥18 years) suspected of or known to have urinary incontinence, regardless of gender or severity. It is ideal for: primary care and emergency department screening to identify patients requiring urology/gynecology referral; routine office-based outcome measurement in urology and gynecology clinics; pre- and post-treatment assessment in patients undergoing incontinence surgery or conservative management; pharmaceutical trials evaluating efficacy of anticholinergics or beta-3 agonists; and epidemiologic surveys of incontinence prevalence in community or institutional populations. Because it is brief and validated cross-culturally, it is particularly useful in settings with time and resource constraints.
Strengths & limitations
- Brevity and feasibility: four items take 1–2 minutes, suitable for routine screening in busy clinical settings without burden to patient or staff.
- Strong psychometric properties: good test–retest reliability (intraclass correlation > 0.92), excellent internal consistency, and robust convergent validity with detailed symptom questionnaires.
- Multidimensional but focused: captures frequency, severity, and impact—the clinically essential dimensions—without over-elaboration.
- Incontinence-type identification: Item 4 prompts patient report of incontinence type, aiding diagnosis of stress, urgency, or mixed incontinence.
- Internationally validated: published in 19+ languages with normative data across diverse populations (gender, age, ethnicity).
- Responsive to treatment: sensitive to improvement following conservative therapy (pelvic floor training, lifestyle modification) and surgical procedures (mid-urethral slings, sacral neuromodulation).
- Limited diagnostic specificity: ICIQ-SF relies on patient self-report of incontinence type; cannot distinguish stress from urgency incontinence with certainty in patients with mixed symptoms.
- No subscale breakdown: all items are summed into a single score; clinicians cannot separately weight frequency vs. impact.
- Four-week recall: respondents may not accurately recall leakage frequency and volume over extended period, especially if symptoms are variable.
- Does not measure symptom pattern: does not capture whether incontinence is predictable (e.g., always with cough) vs. unpredictable, which guides urgency of intervention.
Frequently asked
What total ICIQ-SF score indicates clinically significant incontinence?
A score ≥6 (moderate incontinence) generally warrants clinical evaluation and treatment consideration. Scores 1–5 (slight incontinence) may be monitored without intervention unless the patient is distressed. However, individual patient goals and bother determine intervention threshold; some patients with score 6 may decline treatment, while others with score 4 may pursue options if sufficiently bothered.
Can ICIQ-SF distinguish stress from urgency incontinence?
ICIQ-SF includes Item 4, which asks patients to identify their incontinence type (stress, urgency, mixed, etc.). However, patient perception is not always accurate; formal urodynamic testing may be needed for definitive distinction, especially in mixed incontinence where both mechanisms are present.
How often should the ICIQ-SF be readministered?
There is no universal standard. In clinical practice, baseline ICIQ-SF is obtained, then repeated at follow-up visits (e.g., 6–12 weeks) after initiating treatment or lifestyle modification. In research, follow-up intervals depend on the study design and expected speed of intervention effect.
Is ICIQ-SF suitable for men?
Yes. Although originally developed in women, ICIQ-SF has been validated in men and is recommended by major professional societies for assessing incontinence in both genders. Clinical interpretation is similar, though post-micturition dribble is more prevalent in men and may be reported in Item 4.
Can ICIQ-SF be used in pediatric patients?
ICIQ-SF has not been formally validated in children <18 years. A pediatric-specific version (ICIQ-Child) has been developed and should be used in younger populations. Standard ICIQ-SF is intended for adults.
Sources
- Avery, K., Donovan, J., Peters, T. J., Shaw, C., Gotoh, M., & Abrams, P. (2004). ICIQ: a brief and robust measure for evaluating the symptoms and impact of incontinence. Neurourology and Urodynamics, 23(4), 322–330. DOI: 10.1002/nau.20041 ↗
- Brookes, S. T., Donovan, J. L., Wright, M., Jackson, S., & Abrams, P. (2004). A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: data from a randomized controlled trial of surgery for women with stress incontinence. American Journal of Obstetrics and Gynecology, 191(1), 73–80. DOI: 10.1016/j.ajog.2003.12.027 ↗
How to cite this page
ScholarGate. (2026, June 3). ICIQ Urinary Incontinence Short Form (ICIQ-SF). ScholarGate. https://scholargate.app/en/urology-gynecology/iciq-urinary-incontinence
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Female Sexual Function IndexUrology Gynecology↔ compare
- Overactive Bladder QuestionnaireUrology Gynecology↔ compare
- Pelvic Floor Distress InventoryUrology Gynecology↔ compare